Last updated: 2026-09-09 05:11:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
GeoVax Labs, Inc. New (GOVX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.47, with a market capitalization of $2.52M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.47 to $18.20. This page covers its latest market performance, valuation, price trends and company information.
$2.52M | |
$0.50 | |
$3,266.25 | |
$0.47 | |
$0.48 | |
498.09K | |
683.60K | |
-- | |
$18.20 | |
$0.47 | |
-- | |
-- |
GeoVax Labs, Inc. New (GOVX) last closed at $0.48 as of 2026-09-08 23:23:00, unchanged from the previous close of $0.48.
During the latest regular trading session, GOVX traded between $0.47 and $3,266.25, with a volume of 498.09K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, GeoVax Labs, Inc. New (GOVX) moved from $0.72 to $0.47, representing a decline of 34.45% ($0.25).
The stock traded between $0.47 and $0.88 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 985.02 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.0%
GOVX is currently trading at $0.47, placing it 0.0% of the way from its 52-week low of $0.47 to its 52-week high of $18.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 19 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GeoVax Labs, Inc. New (GOVX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.